Oleg B. Karyakin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oleg B. Karyakin has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
20 shared publications - Sergey Anatolyevich Ivanov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
19 shared publications - Ivan N. Zaborskiy
A.Tsyb Medical Radiological Research Centre – Branch of the National Medical Research Radiological Centre Obninsk, Russian Federation
10 shared publications - V. A. Biryukov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
9 shared publications - Vladimir Chaykov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
9 shared publications - E. O. Shchukina
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
7 shared publications
Latest Publications
- 6 November 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 34
Current State and Critical Challenges in Prostate Cancer Organoid Culture
Three-dimensional prostate cancer organoids represent a promising platform for modeling tumor biology and personalizing therapeutic strategies. However, unlike many other solid tumors, reproducing this pathology in vitro is challenging. Despite initial culture establishment rates reaching 70-90% in certain studies, most cultures undergo early growth arrest (typically within passages P1-P3 or the first 1-2 months), accompanied by a high risk of losing the target tumor clone. In the present work, we provide a critical analysis of the current state of 3D prostate cancer culture technologies and attempt to identify the fundamental reasons for the inefficiency of standard multicomponent media and traditional extracellular matrices. Based on the analysis of single-cell transcriptomic profiling data, we characterized the adaptive drift of organoid cellular composition toward basal and transient states. Furthermore, we substantiated the critical need to modernize approaches for confirming model relevance, particularly by analyzing in detail the limitations of traditional markers. As an effective solution, we propose the concept of integrating multiplex expression test systems based on accessible quantitative PCR platforms, utilizing the extensive arsenal of highly informative RNA biomarkers accumulated in clinical urologic oncology. We conclude that the transition from empirical condition selection to directed niche reconstruction based on single-cell analysis data combined with PCR verification will open new opportunities for the widespread implementation of organoid models in basic research and clinical practice.
- 6 November 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 34
Current State and Critical Challenges in Prostate Cancer Organoid Culture
Three-dimensional prostate cancer organoids represent a promising platform for modeling tumor biology and personalizing therapeutic strategies. However, unlike many other solid tumors, reproducing this pathology in vitro is challenging. Despite initial culture establishment rates reaching 70-90% in certain studies, most cultures undergo early growth arrest (typically within passages P1-P3 or the first 1-2 months), accompanied by a high risk of losing the target tumor clone. In the present work, we provide a critical analysis of the current state of 3D prostate cancer culture technologies and attempt to identify the fundamental reasons for the inefficiency of standard multicomponent media and traditional extracellular matrices. Based on the analysis of single-cell transcriptomic profiling data, we characterized the adaptive drift of organoid cellular composition toward basal and transient states. Furthermore, we substantiated the critical need to modernize approaches for confirming model relevance, particularly by analyzing in detail the limitations of traditional markers. As an effective solution, we propose the concept of integrating multiplex expression test systems based on accessible quantitative PCR platforms, utilizing the extensive arsenal of highly informative RNA biomarkers accumulated in clinical urologic oncology. We conclude that the transition from empirical condition selection to directed niche reconstruction based on single-cell analysis data combined with PCR verification will open new opportunities for the widespread implementation of organoid models in basic research and clinical practice.
- Open Access
- 18 December 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (3) , 170-189
Personalized approach to systemic treatment of bladder cancer: molecular and genetic markers and new therapeutic strategies (literature review)
Platinum-based cytotoxic chemotherapy is widely used in treatment of locally advanced and metastatic bladder cancer (BC) and is the therapy of choice in neoadjuvant treatment of muscle-invasive BC not only in the Russian Federation but worldwide. In the context of predicted significant increase in BC morbidity and mortality in the coming decades, the search for molecular and genetic markers and introduction of complex diagnostic models into clinical practice is relevant that allow for personalized approaches to patient treatment and prevention of BC in order to improve long-term treatment outcomes. Molecular profiling of individual and tumor genomes allows for the identification of markers for assessing sensitivity to standard polychemotherapy regimens, as well as identifying targets for immune and targeted therapy of BC. A literature search conducted in international and domestic databases (NCBI (http://www.ncbi.nlm.nih.gov/), PubMed (https://pubmed.ncbi.nlm.nih.gov/), eLIBRARY.RU (https://www.elibrary.ru/), Google academy (https://scholar.google.ru/)) demonstrated that a wide range of molecular genetic changes are involved in the carcinogenesis of BC. Based on a number of studies, it has been established that alterations in the ERBB2, FGFR3, PIK3CA, RB1, FANCC, DNAH, KDM6A, CDKN2A, MGAM2, RNF213, DDR (MLH1, MSH2/6, PMS1/2, BRCA1/2, CHEK1/2, PALB2, POLE, BLM, ATM, etc.) genes, as well as the expression levels of ERCC1, BRCA1, and CTR1 are associated with the sensitivity of BC to polychemotherapy. In turn, а number of molecular genetic markers are also associated with sensitivity to immunotherapy in BC, including PD-L1 expression, microsatellite instability, high tumor mutational load, APOBEC signatures, CDKN2A/CDKN2B deletions, PD-L1 promoter methylation, as well as alterations of the FGFR3, MDM2, and TP53 genes. In addition, FGFR (fibroblast growth factor receptor) inhibitor – erdafitinib and conjugate of monoclonal antibodies with cytotoxic agents – enfortumab vedotin are recommended for the treatment of BC, having demonstrated their effectiveness in clinical trials. Integration of molecular and genetic diagnostics into clinical oncological practice will improve the accuracy of patient stratification and optimize therapeutic decisions, reducing the risk of unjustified drug load and increasing the effectiveness of systemic treatment.
- 18 December 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (3) , 170-189
Open AccessPersonalized approach to systemic treatment of bladder cancer: molecular and genetic markers and new therapeutic strategies (literature review)
Platinum-based cytotoxic chemotherapy is widely used in treatment of locally advanced and metastatic bladder cancer (BC) and is the therapy of choice in neoadjuvant treatment of muscle-invasive BC not only in the Russian Federation but worldwide. In the context of predicted significant increase in BC morbidity and mortality in the coming decades, the search for molecular and genetic markers and introduction of complex diagnostic models into clinical practice is relevant that allow for personalized approaches to patient treatment and prevention of BC in order to improve long-term treatment outcomes. Molecular profiling of individual and tumor genomes allows for the identification of markers for assessing sensitivity to standard polychemotherapy regimens, as well as identifying targets for immune and targeted therapy of BC. A literature search conducted in international and domestic databases (NCBI (http://www.ncbi.nlm.nih.gov/), PubMed (https://pubmed.ncbi.nlm.nih.gov/), eLIBRARY.RU (https://www.elibrary.ru/), Google academy (https://scholar.google.ru/)) demonstrated that a wide range of molecular genetic changes are involved in the carcinogenesis of BC. Based on a number of studies, it has been established that alterations in the ERBB2, FGFR3, PIK3CA, RB1, FANCC, DNAH, KDM6A, CDKN2A, MGAM2, RNF213, DDR (MLH1, MSH2/6, PMS1/2, BRCA1/2, CHEK1/2, PALB2, POLE, BLM, ATM, etc.) genes, as well as the expression levels of ERCC1, BRCA1, and CTR1 are associated with the sensitivity of BC to polychemotherapy. In turn, а number of molecular genetic markers are also associated with sensitivity to immunotherapy in BC, including PD-L1 expression, microsatellite instability, high tumor mutational load, APOBEC signatures, CDKN2A/CDKN2B deletions, PD-L1 promoter methylation, as well as alterations of the FGFR3, MDM2, and TP53 genes. In addition, FGFR (fibroblast growth factor receptor) inhibitor – erdafitinib and conjugate of monoclonal antibodies with cytotoxic agents – enfortumab vedotin are recommended for the treatment of BC, having demonstrated their effectiveness in clinical trials. Integration of molecular and genetic diagnostics into clinical oncological practice will improve the accuracy of patient stratification and optimize therapeutic decisions, reducing the risk of unjustified drug load and increasing the effectiveness of systemic treatment.
- Open Access
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 198-205
Prospects for molecular profiling in bladder cancer stratification and treatment. A review
Modern trends in oncological care are based on the principles of precision medicine, which necessitates the identification of prognostic and predictive molecular genetic markers. The results of genomic profiling of bladder cancer (BC) represent a wide range of genes involved in carcinogenesis, but the functional significance and clinical potential of most of them have not been sufficiently studied. The aim of this study was to summarize modern scientific and practical data on the trends in precision medicine in the field of oncourology in BC. The materials for the study were domestic and foreign scientific databases, in particular the National Library of Medicine (http://www.ncbi.nlm.nih.gov/) using the electronic resource PubMed (https://pubmed.ncbi.nlm.nih.gov/), eLIBRARY.RU (https://www.elibrary.ru/) and Google Scholar (https://scholar.google.ru/schhp?hl=ru), when searching by keywords: BC, urothelial carcinoma, NGS, molecular profiling, genes, FGFR3, TERT, PIK3CA, TP53, mutations, expression. An analytical review concerning clinical, pathomorphological and molecular genetic data on the problems of diagnosis and treatment of BC included reports on preclinical experimental and clinical studies, meta-analyses, systematic reviews, cohort randomized studies for the period 2002–2025. A number of studies have demonstrated the association of molecular genetic changes in genes encoding receptor and intracellular kinases (FGFR2/3, PIK3CA etc.) with early stages of BC carcinogenesis, provided that the multifactorial prognostic significance is variable, taking into account the availability of modern molecular-targeted drugs. In particular, a pan-FGFR inhibitor, erdafitinib, which has demonstrated its effectiveness, is currently approved for the treatment of common forms of BC. Taking into account the pathogenetic mechanisms, an important further prospect for the use of receptor and intracellular kinase inhibitors in BC is the development and introduction into clinical practice of highly selective systemic and locally delivered forms with the possibility of their use in clinically heterogeneous groups of patients, including those with early stages of the disease. In turn, alterations in genes responsible for DNA repair (TP53, etc.) are associated with an aggressive course of the disease and a corresponding less favorable prognosis. In this direction, the key point of application of personalized therapy is the development and use of agents capable of modulating the activity of proteins of the reparation system at various stages of carcinogenesis. Thus, the mutational and functional status of genes involved in key oncogenic and reparation pathways in BC plays an important role in the context of developing a prognostic model, and also serves as a predictive target for therapeutic intervention.
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 198-205
Open AccessProspects for molecular profiling in bladder cancer stratification and treatment. A review
Modern trends in oncological care are based on the principles of precision medicine, which necessitates the identification of prognostic and predictive molecular genetic markers. The results of genomic profiling of bladder cancer (BC) represent a wide range of genes involved in carcinogenesis, but the functional significance and clinical potential of most of them have not been sufficiently studied. The aim of this study was to summarize modern scientific and practical data on the trends in precision medicine in the field of oncourology in BC. The materials for the study were domestic and foreign scientific databases, in particular the National Library of Medicine (http://www.ncbi.nlm.nih.gov/) using the electronic resource PubMed (https://pubmed.ncbi.nlm.nih.gov/), eLIBRARY.RU (https://www.elibrary.ru/) and Google Scholar (https://scholar.google.ru/schhp?hl=ru), when searching by keywords: BC, urothelial carcinoma, NGS, molecular profiling, genes, FGFR3, TERT, PIK3CA, TP53, mutations, expression. An analytical review concerning clinical, pathomorphological and molecular genetic data on the problems of diagnosis and treatment of BC included reports on preclinical experimental and clinical studies, meta-analyses, systematic reviews, cohort randomized studies for the period 2002–2025. A number of studies have demonstrated the association of molecular genetic changes in genes encoding receptor and intracellular kinases (FGFR2/3, PIK3CA etc.) with early stages of BC carcinogenesis, provided that the multifactorial prognostic significance is variable, taking into account the availability of modern molecular-targeted drugs. In particular, a pan-FGFR inhibitor, erdafitinib, which has demonstrated its effectiveness, is currently approved for the treatment of common forms of BC. Taking into account the pathogenetic mechanisms, an important further prospect for the use of receptor and intracellular kinase inhibitors in BC is the development and introduction into clinical practice of highly selective systemic and locally delivered forms with the possibility of their use in clinically heterogeneous groups of patients, including those with early stages of the disease. In turn, alterations in genes responsible for DNA repair (TP53, etc.) are associated with an aggressive course of the disease and a corresponding less favorable prognosis. In this direction, the key point of application of personalized therapy is the development and use of agents capable of modulating the activity of proteins of the reparation system at various stages of carcinogenesis. Thus, the mutational and functional status of genes involved in key oncogenic and reparation pathways in BC plays an important role in the context of developing a prognostic model, and also serves as a predictive target for therapeutic intervention.
- Open Access
- 9 September 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (3) , 8-20
Morphological and laboratory factors associated with recurrence risk in non-metastatic seminoma pT1–pT2: a retrospective analysis
Морфологические и лабораторные факторы, ассоциированные с риском рецидива при неметастатической семиноме pT1–pT2 стадий: ретроспективный анализ
- 9 September 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (3) , 8-20
Open AccessMorphological and laboratory factors associated with recurrence risk in non-metastatic seminoma pT1–pT2: a retrospective analysis
Морфологические и лабораторные факторы, ассоциированные с риском рецидива при неметастатической семиноме pT1–pT2 стадий: ретроспективный анализ
- Open Access
- 14 August 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (3) , 129
Phenotypic and Spatial Characterization of Tumor-Associated Macrophages in Non-Metastatic Seminoma: Association with Local Tumor Progression
Background: Seminoma is the most common subtype of testicular germ cell tumors in young men; however, the contribution of tumor-associated macrophages (TAMs) to disease progression remains insufficiently understood. This study aimed to quantitatively and phenotypically characterize CD68+ and CD163+ TAMs in non-metastatic seminomas (pT1N0M0 and pT2N0M0). Methods: This retrospective, multicenter, cohort, observational, analytical study was conducted from 1 January 2015 to 1 January 2025 at two branches of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation: the A. Tsyb Medical Radiological Research Center and the P. Hertsen Moscow Oncology Research Institute. Archived paraffin-embedded tumor samples from 96 patients and 21 samples of normal testicular tissue were analyzed using immunohistochemistry and digital morphometric analysis with QuPath software to assess macrophage density and spatial distribution. Results: Compared to normal testicular tissue, seminomas demonstrated more than a 10-fold increase in CD68+ TAMs and over a 100-fold increase in CD163+ TAMs. CD68+ cells predominantly localized to peripheral tumor regions, while CD163+ cells formed diffuse clusters in central tumor zones and around peripheral vessels. No statistically significant differences in CD68+ cell density were found between pT1 and pT2 stages. However, pT2 tumors showed a trend toward higher CD163+ TAMs density, suggesting increased M2 polarization with advancing tumor stage. Conclusions: These findings highlight the spatial and phenotypic heterogeneity of TAMs in seminoma and indicate a shift toward an immunosuppressive tumor microenvironment during local progression. Future studies should assess macrophage polarization and progression-free survival to evaluate their potential as prognostic biomarkers and therapeutic targets in seminoma.
- 14 August 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (3) , 129
Open AccessPhenotypic and Spatial Characterization of Tumor-Associated Macrophages in Non-Metastatic Seminoma: Association with Local Tumor Progression
Background: Seminoma is the most common subtype of testicular germ cell tumors in young men; however, the contribution of tumor-associated macrophages (TAMs) to disease progression remains insufficiently understood. This study aimed to quantitatively and phenotypically characterize CD68+ and CD163+ TAMs in non-metastatic seminomas (pT1N0M0 and pT2N0M0). Methods: This retrospective, multicenter, cohort, observational, analytical study was conducted from 1 January 2015 to 1 January 2025 at two branches of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation: the A. Tsyb Medical Radiological Research Center and the P. Hertsen Moscow Oncology Research Institute. Archived paraffin-embedded tumor samples from 96 patients and 21 samples of normal testicular tissue were analyzed using immunohistochemistry and digital morphometric analysis with QuPath software to assess macrophage density and spatial distribution. Results: Compared to normal testicular tissue, seminomas demonstrated more than a 10-fold increase in CD68+ TAMs and over a 100-fold increase in CD163+ TAMs. CD68+ cells predominantly localized to peripheral tumor regions, while CD163+ cells formed diffuse clusters in central tumor zones and around peripheral vessels. No statistically significant differences in CD68+ cell density were found between pT1 and pT2 stages. However, pT2 tumors showed a trend toward higher CD163+ TAMs density, suggesting increased M2 polarization with advancing tumor stage. Conclusions: These findings highlight the spatial and phenotypic heterogeneity of TAMs in seminoma and indicate a shift toward an immunosuppressive tumor microenvironment during local progression. Future studies should assess macrophage polarization and progression-free survival to evaluate their potential as prognostic biomarkers and therapeutic targets in seminoma.
- Open Access
- 22 November 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (3) , 67-79
Side effects and complications of high dose-rate brachytherapy: literature review and our own observations
Background. Among malignant tumors in men in Russia, prostate cancer is the most common comprising 17 %. Despite the high effectiveness of radiotherapy for prostate cancer in about 20 % of patients, radiation damage of the pelvic organs develops affecting bladder, rectum, and intrapelvic cellular tissue.Aim. To evaluate early and late complications of high dose-rate brachytherapy.Materials and methods. Literature review was performed, and our own results of treatment of 276 patients using high dose-rate brachytherapy as monotherapy with different fractionation regimens: 19 Gy per 1 fraction and 15 Gy per 2 fractions were analyzed.Results. High dose-rate brachytherapy as monotherapy is associated with low complication rate. There were no statistically significant differences between singleand two-fraction regimens. Evaluation of complication severity per the RTOG (Radiation Therapy Oncology Group) classification did not show complication severity above grade III. Early complications were diagnosed in 1.1 %, late in 3.3 % of cases. Between the treatment and comparison groups, no statistically significant differences in the frequency of urinary system organ symptoms per the IPSS (International Prostate Symptom Score) questionnaire were registered. Mean score per the IPSS prior to treatment was 4.0 (3.0–6.0) in the treatment group and 4.0 (3.0–8.5) in the comparison group. Mean follow-up duration in the treatment group was 65.0 (60.0–70.0) months, in the comparison group – 55.0 (49.5–65.0) months. After the treatment, mean IPSS score was 5.0 (4.0–5.0) in the treatment group and 5.0 (3.0–7.0) in the comparison group.Conclusion. High dose-rate brachytherapy as monotherapy and in combination with external beam therapy is a safe and effective treatment method in prostate cancer. Serious and late complications are rare, however toxic effects of severity grades I or II can develop. Careful patient selection for brachytherapy, therapy planning methods, as well as active management of early and late toxicity by a multidisciplinary team with knowledge and experience in treatment of side effects of radiotherapy can help optimize treatment with high dose-rate brachytherapy.
- 22 November 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (3) , 67-79
Open AccessSide effects and complications of high dose-rate brachytherapy: literature review and our own observations
Background. Among malignant tumors in men in Russia, prostate cancer is the most common comprising 17 %. Despite the high effectiveness of radiotherapy for prostate cancer in about 20 % of patients, radiation damage of the pelvic organs develops affecting bladder, rectum, and intrapelvic cellular tissue.Aim. To evaluate early and late complications of high dose-rate brachytherapy.Materials and methods. Literature review was performed, and our own results of treatment of 276 patients using high dose-rate brachytherapy as monotherapy with different fractionation regimens: 19 Gy per 1 fraction and 15 Gy per 2 fractions were analyzed.Results. High dose-rate brachytherapy as monotherapy is associated with low complication rate. There were no statistically significant differences between singleand two-fraction regimens. Evaluation of complication severity per the RTOG (Radiation Therapy Oncology Group) classification did not show complication severity above grade III. Early complications were diagnosed in 1.1 %, late in 3.3 % of cases. Between the treatment and comparison groups, no statistically significant differences in the frequency of urinary system organ symptoms per the IPSS (International Prostate Symptom Score) questionnaire were registered. Mean score per the IPSS prior to treatment was 4.0 (3.0–6.0) in the treatment group and 4.0 (3.0–8.5) in the comparison group. Mean follow-up duration in the treatment group was 65.0 (60.0–70.0) months, in the comparison group – 55.0 (49.5–65.0) months. After the treatment, mean IPSS score was 5.0 (4.0–5.0) in the treatment group and 5.0 (3.0–7.0) in the comparison group.Conclusion. High dose-rate brachytherapy as monotherapy and in combination with external beam therapy is a safe and effective treatment method in prostate cancer. Serious and late complications are rare, however toxic effects of severity grades I or II can develop. Careful patient selection for brachytherapy, therapy planning methods, as well as active management of early and late toxicity by a multidisciplinary team with knowledge and experience in treatment of side effects of radiotherapy can help optimize treatment with high dose-rate brachytherapy.
- Open Access
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 140-147
Brachytherapy for organ-preserving treatment of bladder cancer
Bladder cancer is the 9th most common malignant tumor worldwide. Muscle-invasive bladder cancer is an aggressive malignant neoplasm with a tendency for early metastases. The main approach for muscle-invasive bladder cancer treatment is radical cystectomy with lymph node dissection and polychemotherapy. In recent decades, organ-preserving conservative therapy has been actively investigated. Currently, the most studied approach to organ-preserving treatment of muscle-invasive bladder cancer is the trimodality therapy which includes transurethral resection of the bladder wall with the tumor, chemotherapy, and external beam radiotherapy. The article presents an approach which additionally includes intratumoral radiation therapy. In our study, we have investigated the current state of brachytherapy in bladder cancer treatment and its development.
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 140-147
Open AccessBrachytherapy for organ-preserving treatment of bladder cancer
Bladder cancer is the 9th most common malignant tumor worldwide. Muscle-invasive bladder cancer is an aggressive malignant neoplasm with a tendency for early metastases. The main approach for muscle-invasive bladder cancer treatment is radical cystectomy with lymph node dissection and polychemotherapy. In recent decades, organ-preserving conservative therapy has been actively investigated. Currently, the most studied approach to organ-preserving treatment of muscle-invasive bladder cancer is the trimodality therapy which includes transurethral resection of the bladder wall with the tumor, chemotherapy, and external beam radiotherapy. The article presents an approach which additionally includes intratumoral radiation therapy. In our study, we have investigated the current state of brachytherapy in bladder cancer treatment and its development.
- Open Access
- 25 September 2023
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 16 (3) , 136-145
High-dose-rate brachytherapy as monotherapy in patients with localized prostate cancer.
Introduction. Prostate cancer is the second most common cancer among men. In Russia the number of patients with stage I-II prostate cancer increased from 47,7% in 2010 to 60,7% in 2021. One of the mai
- 25 September 2023
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 16 (3) , 136-145
Open AccessHigh-dose-rate brachytherapy as monotherapy in patients with localized prostate cancer.
Introduction. Prostate cancer is the second most common cancer among men. In Russia the number of patients with stage I-II prostate cancer increased from 47,7% in 2010 to 60,7% in 2021. One of the mai
- Open Access
- 13 August 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (2) , 111-126-126
Biomarkers determining treatment tactics in metastatic urothelial cancer
The implementation of innovative methods of drug therapy and biotherapy into clinical practice has significantly changed the treatment tactics for metastatic urothelial cancer. Currently, treatment regimens are successfully supplemented with immunotherapy (immune checkpoint inhibitors) or targeted therapy, and the effectiveness of such combinations can be quite high, but the optimal sequence of different types of drug therapy remains to be established. The development of correct algorithms using reliable biomarkers is necessary to select the correct sequence of prescribing drugs. Until now, the expression of programmed cell death-ligand 1 (PD-L1) and changes in fibroblast growth factor receptors 1–4 (FGFR1–4) have been the fundamental markers for choosing alternative treatment regimens for metastatic urothelial cancer. At the same time, the list of useful and sufficiently informative biomarkers is expanding, and therefore we tried to summarize the available data on the known biological markers for selection of treatment tactics for metastatic urothelial cancer.
- 13 August 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (2) , 111-126-126
Open AccessBiomarkers determining treatment tactics in metastatic urothelial cancer
The implementation of innovative methods of drug therapy and biotherapy into clinical practice has significantly changed the treatment tactics for metastatic urothelial cancer. Currently, treatment regimens are successfully supplemented with immunotherapy (immune checkpoint inhibitors) or targeted therapy, and the effectiveness of such combinations can be quite high, but the optimal sequence of different types of drug therapy remains to be established. The development of correct algorithms using reliable biomarkers is necessary to select the correct sequence of prescribing drugs. Until now, the expression of programmed cell death-ligand 1 (PD-L1) and changes in fibroblast growth factor receptors 1–4 (FGFR1–4) have been the fundamental markers for choosing alternative treatment regimens for metastatic urothelial cancer. At the same time, the list of useful and sufficiently informative biomarkers is expanding, and therefore we tried to summarize the available data on the known biological markers for selection of treatment tactics for metastatic urothelial cancer.
- Open Access
- 18 May 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (2) , 31-39
Combined treatment of high and very high risk prostate cancer: results of neoadjuvant treatment
Purpose of the study. Assessment of safety and short‑term effectiveness of high and very high‑risk prostate cancer neoadjuvant chemo‑ hormonal treatment without distant metastases.Patients and methods. Combined hormone chemo‑ radiation treatment of 33 patients with prostate cancer of high and very high risk of progression without distant metastases was performed. Metastases to regional lymph nodes were found in 9 patients according to the examination data (MRI, MSCT), no metastases were detected in 24 patients. All patients underwent combined chemohormonal therapy in the amount of 4 courses of docetaxel intravenously at a dose of 75 mg/m2 every 3 weeks as the first stage of treatment. in combination with androgen deprivation therapy with agonists or antagonists of GnRH before performing radical radiation therapy (combined or remote). All patients underwent neoadjuvant hormone therapy: 16 patients – with the use of GnRH antagonists (Degarelix), 17 – with the use of GnRH agonists (Gozerelin/Leuprorelin/Triptorelin). The toxicity of the presented treatment regimen and its immediate effectiveness – the effect on the level of prostate‑s pecific antigen (PSA), prostate volume, and the quality of urination – were evaluated.Results. Treatment regimen was highly effective concerning PSA decrease (from initial median level 79,67 ng/ml to 1,45 ng/ml after neoadjuvant treatment), all subjects responded well, no non‑responders observed. Median prostate volume decreased from 44 cm3 to 25 cm3 after treatment, which guaranteed availability and safety of further radical radiation treatment. Urinary function was restored in all subject with initial urinary retention.Conclusion. Neoadjuvant chemo‑h ormonal treatment was highly effective in PSA level, prostate volume decrease and functional results improvement which secured further radical radiation treatment in one of its types. Toxicity was acceptable, adverse events did not exceed grade II in most cases and did not lead to treatment discontinuation in any cases, while quality of life remained high enough.
- 18 May 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (2) , 31-39
Open AccessCombined treatment of high and very high risk prostate cancer: results of neoadjuvant treatment
Purpose of the study. Assessment of safety and short‑term effectiveness of high and very high‑risk prostate cancer neoadjuvant chemo‑ hormonal treatment without distant metastases.Patients and methods. Combined hormone chemo‑ radiation treatment of 33 patients with prostate cancer of high and very high risk of progression without distant metastases was performed. Metastases to regional lymph nodes were found in 9 patients according to the examination data (MRI, MSCT), no metastases were detected in 24 patients. All patients underwent combined chemohormonal therapy in the amount of 4 courses of docetaxel intravenously at a dose of 75 mg/m2 every 3 weeks as the first stage of treatment. in combination with androgen deprivation therapy with agonists or antagonists of GnRH before performing radical radiation therapy (combined or remote). All patients underwent neoadjuvant hormone therapy: 16 patients – with the use of GnRH antagonists (Degarelix), 17 – with the use of GnRH agonists (Gozerelin/Leuprorelin/Triptorelin). The toxicity of the presented treatment regimen and its immediate effectiveness – the effect on the level of prostate‑s pecific antigen (PSA), prostate volume, and the quality of urination – were evaluated.Results. Treatment regimen was highly effective concerning PSA decrease (from initial median level 79,67 ng/ml to 1,45 ng/ml after neoadjuvant treatment), all subjects responded well, no non‑responders observed. Median prostate volume decreased from 44 cm3 to 25 cm3 after treatment, which guaranteed availability and safety of further radical radiation treatment. Urinary function was restored in all subject with initial urinary retention.Conclusion. Neoadjuvant chemo‑h ormonal treatment was highly effective in PSA level, prostate volume decrease and functional results improvement which secured further radical radiation treatment in one of its types. Toxicity was acceptable, adverse events did not exceed grade II in most cases and did not lead to treatment discontinuation in any cases, while quality of life remained high enough.